Slide
"I am a 45 year old former Ironman...
hoping to avoid a hip replacement at all costs."

- Early OA Patient
Slide
"I am 52, active...young in every way
except my hip"

- Early OA Patient
Slide
"A hip replacement at 35 is nonsense and would
mean the end of my career as a dancer."

- Early OA Patient
Slide

- Dr. Thomas Vail, University of California, San Francisco
"Orthopedic surgeons have been waiting for cartilage resurfacing technology for years. If efficacy can be shown, this technology will rapidly be adopted.”

This is an Untapped Market

People In the United States Suffer From Osteoarthritis

14-55

Age Range: Aimed at Younger Patients Suffering from OA

The Growing Hip Preservation Market is worth Billions

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Our Technology?

Expertise and Innovation

Sign up for Business News

Questions

About the

Technology?

Expertise and Innovation

Sign up for Business News

News

Newsletter – June 2023

Newsletter – June 2023

The June issue of the CytexOrtho newsletter covers our successful crowdfunding raise, our progress toward clinical trials, and our talk on capitol hill! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists via the...

read more
CytexOrtho on Capital Hill

CytexOrtho on Capital Hill

On May 11th, 2023 Dr Brad Estes, CytexOrtho Co-founder and CEO, traveled to Washington D.C. to sit on a panel about the state of osteoarthritis (OA) in the United States, and the need for additional funding to move scientific advances combating OA to the clinic. The...

read more
Breakthrough Device Designation from the FDA

Breakthrough Device Designation from the FDA

  We are thrilled to announce that we just received a Breakthrough Device Designation from the United States Food and Drug Administration (FDA) for our novel hip cartilage repair technology. The intent of the Breakthrough Devices Program1 is to help patients have...

read more

News

Newsletter – June 2023

Newsletter – June 2023

The June issue of the CytexOrtho newsletter covers our successful crowdfunding raise, our progress toward clinical trials, and our talk on capitol hill! If you would like to receive a copy of our future newsletters, be sure to sign up for our mailing lists via the...

read more
CytexOrtho on Capital Hill

CytexOrtho on Capital Hill

On May 11th, 2023 Dr Brad Estes, CytexOrtho Co-founder and CEO, traveled to Washington D.C. to sit on a panel about the state of osteoarthritis (OA) in the United States, and the need for additional funding to move scientific advances combating OA to the clinic. The...

read more
Breakthrough Device Designation from the FDA

Breakthrough Device Designation from the FDA

  We are thrilled to announce that we just received a Breakthrough Device Designation from the United States Food and Drug Administration (FDA) for our novel hip cartilage repair technology. The intent of the Breakthrough Devices Program1 is to help patients have...

read more